Over the past two decades, elucidation of the genetic defects that underlie cancer has
resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be …

Remarkable progress has been made in the development of biomarker-driven targeted
therapies for patients with multiple cancer types, including melanoma, breast and lung …

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor patient
survival. Toward understanding the underlying molecular alterations that drive PDAC …

Combinatorial therapies have been recently proposed to improve the efficacy of anticancer
treatment. The SynergyFinder R package is a software used to analyze pre-clinical drug …

Mutational loss of CDKN2A (encoding p16INK4A) tumor-suppressor function is a key
genetic step that complements activation of KRAS in promoting the development and …

Around 20% of all malignancies harbour activating mutations in RAS isoforms. Despite this,
there is a deficiency of RAS-targeting agents licensed for therapeutic use. The picomolar …

KRAS, one of the RAS protein family members, plays an important role in autophagy and
apoptosis, through the regulation of several downstream effectors. In cancer cells, KRAS …

Missense mutations at the three hotspots in the guanosine triphosphatase (GTPase) RAS—
Gly12, Gly13, and Gln61 (commonly known as G12, G13, and Q61, respectively)—occur …

In-frame BRAF exon 12 deletions are increasingly identified in various tumor types. The
resultant BRAFΔβ3-αC oncoproteins usually lack five amino acids in the β3-αC helix linker …

The aggressive nature of pancreatic ductal adenocarcinoma (PDAC) mandates the
development of improved therapies. As KRAS mutations are found in 95% of PDAC and are …